Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab as Adjuvant Treatment for Early-Stage High-Risk Breast Cancer
2009-011299-32Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Denosumab with Placebo (2 arms). Primary endpoint: Bone metastasis-free survival. Started Apr 2010; status: completed.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-011299-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011299-32.